• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Sharon Kingman

Articles by Sharon Kingman

Drive to Inhibit 'Master Switch' for Tumor Embryonic Growth

Feb. 27, 2013
By Sharon Kingman
LONDON – Identification of a protein that orchestrates many of the changes that permit a normal cell to turn into a cancer cell will open up an entirely new field of cancer therapeutics, the researchers who made the discovery predicted.
Read More

Biosimilars Panel: Return to Starting Block for 'Biobetters'

Feb. 22, 2013
By Sharon Kingman
LONDON – While the development of biosimilars – biological medicines designed to be very similar to ones that have already been approved for clinical use – is really still in its infancy, people already are looking to the future and considering what sorts of molecules will come next.
Read More

Seeing Double: Proving that Molecules Are Similar Enough

Feb. 21, 2013
By Sharon Kingman
LONDON – How different does a drawing of an elephant have to be before it stops looking like an elephant? How similar does a fingerprint have to be before we can say it is the same as the one found at the crime scene?
Read More

Pushing, Pulling Biosimilars to European Marketplace

Feb. 21, 2013
By Sharon Kingman
LONDON – If the European market for biosimilars could be worth $4 billion by 2017, why has progress been so slow in gaining market authorizations for biosimilars in recent years?
Read More

Biosimilar MAbs Starting to Line Up for Approval

Feb. 20, 2013
By Sharon Kingman
LONDON – 2013 will be a watershed year for biosimilars – biological therapies designed to be similar to existing biological therapeutic agents – delegates attending the Second Biosimilars Congregation in London heard Tuesday.
Read More

Biosimilar MAbs Starting to Line up for Approval

Feb. 20, 2013
By Sharon Kingman
LONDON – 2013 will be a watershed year for biosimilars – biological therapies designed to be similar to existing biological therapeutic agents – delegates attending the Second Biosimilars Congregation in London heard Tuesday.
Read More

Scientists Direct Focus on Targeting Short-Sight Genes

Feb. 13, 2013
By Sharon Kingman
With the discovery of 24 new genes that are linked to myopia, or short-sightedness, most of the hereditary causes of this condition are now known, researchers contend.
Read More

Control of Cancer, Not Killing, Is Key to Treatment: Study

Feb. 6, 2013
By Sharon Kingman
Successful treatment of cancer depends not on killing tumor cells, but in beating them into submission using the immune system, a team of German researchers reported. They have identified a type of immune cell that can "re-educate" cancer cells, so that they enter prolonged periods of growth arrest.
Read More

Control of Cancer, Not Killing, Is Key to Treatment: Study

Feb. 6, 2013
By Sharon Kingman
Successful treatment of cancer depends not on killing tumor cells, but in beating them into submission using the immune system, a team of German researchers reported. They have identified a type of immune cell that can "re-educate" cancer cells, so that they enter prolonged periods of growth arrest.
Read More

Genetic Study Reveals 'Critical' Gene in Melanoma Development

Jan. 30, 2013
By Sharon Kingman
A family that has 14 members affected by an aggressive form of malignant melanoma has helped researchers discover a new mutation that is common in melanoma tumors and could lead to new, targeted treatments for that type of cancer.
Read More
Previous 1 2 … 7 8 9 10 11 12 13 14 15 … 107 108 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 28, 2025.
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Salvia Bioelectronics MySalvia implant

    Salvia raises $60M for neuromodulation migraine system

    BioWorld MedTech
    Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe